Abstract:Human β defensin type 2 (hBD-2), a cationic cysteine-rich peptide secreted from the human innate immune system, can bind Spike-RBD at the same site as receptor ACE2, thus blocking viral entry into ACE2-expressing cells. In order to find out the impact of CoV-2 mutations on hBD-2's antiviral activity, it is important to investigate the binding and interaction of hBD-2 with RBD mutants. All-atom molecular dynamics simulations were conducted on typical RBD mutants, including N501Y, E484K, P479S, T478I, S477N, N439K, K417N, and N501Y-E484K-K417N, binding with hBD-2. Starting from the stable binding structure of hBD-2 and wt-RBD and ClusPro and HADDOCK docking-predicted initial structures, the RBD variants bound with hBD-2 simulations were set up, and NAMD simulations were conducted. Based on the structure and dynamics analysis, it was found that most RBD variants can still form a similar number of hydrogen bonds with hBD-2, in addition to having a similar-sized buried surface area (BSA) and a similar binding interface to the RBD wildtype. However, the RBD triple mutant formed a less stable binding structure with hBD-2 than other variants. Additionally, the free energy perturbation (FEP) method was applied to calculate the contribution of key mutant residues to the binding and the free energy change caused by the mutations. The result shows that N439K, K417N, and the trimutation increase the binding free energy of RBD with hBD-2; thus, RBD should bind less stably with hBD-2. E484K decreases the binding free energy, thus it should bind more stably with hBD-2, while N501Y, S477N, T478I, and P479S almost do not change the binding free energy with hBD-2. The MM-GBSA method predicted the binding interaction energy which shows that the trimutant should be able to escape the binding with hBD-2 but N501Y should not. The result can provide insight into understanding the functional mechanism of hBD-2 combating SARS-CoV-2 mutants.

Expression of Human β-defensin 2 (hBD-2) in Pichia Pastoris and Investigation of Its Binding Efficiency with ACE-2

Cloning and Expression of Human Beta-Defensin-2 Gene in Escherichia Coli

Preferential codons enhancing the expression level of human beta-defensin-2 in recombinant Escherichia coli.

Expression of human β-defensin-2 with multiple joined genes in Escherichia coli

Expression of human beta-defensin-2 with multiple joined genes in Escherichia coli.

Molecular Dynamics Simulations on Spike Protein Mutants Binding with Human β Defensin Type 2

Recent advances in the research and development of human defensins.

Fusion expression of human beta-defensin-2 from multiple joined genes in Escherichia coli.

High-level Expression of Soluble Human Β-Defensin-2 in Escherichia Coli

Expression and Characterization of Recombinant Porcine Β-Defensin-2 Gene in Pichia Pastoris

Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry

Human β-defensin 2: a connection between infections and allergic skin diseases

Human β-Defensin 2 Mediated Immune Modulation as Treatment for Experimental Colitis

[Construction and Expression of Recombinant Adenovirus Expression Vector of Beta-Defensin-2].

Soluble fusion expression and characterization of bioactive human beta-defensin 26 and 27

Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo

[Advances in the Research of Human Defensins].

Structural Analysis of Human β-Defensin-1 and Its Significance in Urinary Tract Infection

Protective Efficacy of Novel Engineered Human ACE2-Fc Fusion Protein Against Pan-SARS-CoV-2 Infection In Vitro and in Vivo

Study of Potential Blocking Peptides Targeting the SARS-CoV-2 RBD/hACE2 Interaction

GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2